The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.
Enhanced half-life factor VIII and IX products are being introduced into routine clinical practice. Published data report on clinical trials and there are limited data available on how to use these products in routine clinical practice. Many patients, for example, those with a past history of an inhibitor, have been excluded from clinical trials and there are limited data published on children. This guidance document is a consensus statement from the UK Haemophilia Centres Doctors' Organisation and aims to give pragmatic advice on the use of these products in routine practice.
Arthur Bloom Haemophilia Centre, University Hospital of Wales, Cardiff, UK.
P
P
Collins
Haemophilia Centre, Royal Hospital for Sick Children, Glasgow, UK.
E
E
Chalmers
Katharine Dormandy Haemophilia Centre, Royal Free Hospital, London, UK.
P
P
Chowdary
Haemophilia Centre, Churchill Hospital, Oxford, UK.
D
D
Keeling
Haemophilia Centre, Great Ormond Street Hospital, London, UK.
M
M
Mathias
Haemophilia Centre, St. James Hospital, Dublin, Ireland.
J
J
O'Donnell
Haemophilia Centre, Royal London Hospital, London, UK.
K J
KJ
Pasi
Haemophilia Centre, Basingstoke and North Hampshire Hospital, Basingstoke, UK.
S
S
Rangarajan
Haemophilia Centre, Royal Infirmary of Edinburgh, Edinburgh, UK.
A
A
Thomas
D057134:Antibodies, Neutralizing / Q000097:blood; D003029:Coagulants / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005164:Factor IX / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005169:Factor VIII / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006207:Half-Life; D006467:Hemophilia A / Q000188:drug therapy*; D002836:Hemophilia B / Q000188:drug therapy*; D006470:Hemorrhage / Q000517:prevention & control; D006801:Humans; D011092:Polyethylene Glycols / Q000737:chemistry; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000493:pharmacokinetics / Q000627:therapeutic use
D057134:Antibodies, Neutralizing; D003029:Coagulants; D011993:Recombinant Fusion Proteins; D011092:Polyethylene Glycols; D005169:Factor VIII; D005164:Factor IX
coagulation factor concentrates; enhanced half-life; pharmacokinetics; prophylaxis